CancerDrs

Head and Neck Cancer clinical trials in South Carolina

23 actively recruiting head and neck cancer trials at 18 sites across South Carolina.

Data from ClinicalTrials.gov · last refreshed

Phase 2, Phase 3 Recruiting NIH

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

This phase II/III trial studies how well radiation therapy works when given together with cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery in treating patients with high-risk stage III-IV head and neck cancer the begins i…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT01810913
Sites in South Carolina:
  • AnMed Health Cancer Center — Anderson, South Carolina
  • Saint Joseph's/Candler - Bluffton Campus — Bluffton, South Carolina
  • Prisma Health Cancer Institute - Spartanburg — Boiling Springs, South Carolina
  • Medical University of South Carolina — Charleston, South Carolina
  • Prisma Health Cancer Institute - Faris — Greenville, South Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting NIH

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

This phase III trial compares the effect of adding cetuximab to pembrolizumab versus pembrolizumab alone in treating patients with head and neck squamous cell carcinoma (HNSCC) that has come back after a period of improvement (recurrent) a…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06589804
Sites in South Carolina:
  • Medical University of South Carolina — Charleston, South Carolina
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Academic/Other

Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer

This phase II/III trial studies how well sentinel lymph node biopsy works and compares sentinel lymph node biopsy surgery to standard neck dissection as part of the treatment for early-stage oral cavity cancer. Sentinel lymph node biopsy s…

Sponsor: NRG Oncology
NCT ID: NCT04333537
Sites in South Carolina:
  • Medical University of South Carolina — Charleston, South Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)

This is a phase 3 open-label, randomized, controlled, multicenter study to compare petosemtamab vs investigator's choice monotherapy in HNSCC patients for the second- and third-line treatment of incurable metastatic/recurrent disease.

Sponsor: Merus B.V.
NCT ID: NCT06496178
Sites in South Carolina:
  • Site 50 — Charleston, South Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

The goal of this study is to assess the safety and effectiveness of Dostarlimab compared to Placebo in adult participants with Head and Neck Squamous Cell Carcinoma (HNSCC)

Sponsor: GlaxoSmithKline
NCT ID: NCT06256588
Sites in South Carolina:
  • GSK Investigational Site — Charleston, South Carolina
  • GSK Investigational Site — Greenville, South Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

The purpose of this study is to compare the efficacy and safety of ficlatuzumab plus cetuximab compared to placebo plus cetuximab in participants with recurrent/metastatic (R/M) HPV-negative Head and Neck Cancer. The primary hypothesis is …

Sponsor: AVEO Pharmaceuticals, Inc.
NCT ID: NCT06064877
Sites in South Carolina:
  • Medical University of South Carolina (MUSC) — Charleston, South Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

This phase II trial studies how well radiation therapy with or without cisplatin works in treating patients with stage III-IVA squamous cell carcinoma of the head and neck who have undergone surgery. Radiation therapy uses high energy x-ra…

Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT02734537
Sites in South Carolina:
  • Prisma Health Cancer Institute - Spartanburg — Boiling Springs, South Carolina
  • Medical University of South Carolina — Charleston, South Carolina
  • Prisma Health Cancer Institute - Easley — Easley, South Carolina
  • Prisma Health Cancer Institute - Butternut — Greenville, South Carolina
  • Prisma Health Cancer Institute - Faris — Greenville, South Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

This phase II trial studies the effect of pembrolizumab alone compared to the usual approach (chemotherapy \[cisplatin and carboplatin\] plus radiation therapy) after surgery in treating patients with head and neck squamous cell carcinoma …

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04671667
Sites in South Carolina:
  • Medical University of South Carolina — Charleston, South Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

This phase II trial compares the effectiveness of adding BMX-001 to usual symptom management versus usual symptom management alone for reducing oral mucositis in patients who are receiving chemoradiation for head and neck cancer. Oral muco…

Sponsor: NRG Oncology
NCT ID: NCT06532279
Sites in South Carolina:
  • Lancaster Radiation Therapy Center — Lancaster, South Carolina
  • Rock Hill Radiation Therapy Center — Rock Hill, South Carolina
  • Levine Cancer Institute-Rock Hill — Rock Hill, South Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

This phase II trial compares the effect of usual treatment of docetaxel chemotherapy plus trastuzumab, to ado-emtansine (T-DM1) in patients with HER2-postive salivary gland cancer that has come back (recurrent), that has spread from where …

Sponsor: NRG Oncology
NCT ID: NCT05408845
Sites in South Carolina:
  • Medical University of South Carolina — Charleston, South Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)

This phase II trial tests effects of nivolumab in combination with chemotherapy drugs prior to radiation therapy patients with nasopharyngeal carcinoma (NPC). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06064097
Sites in South Carolina:
  • Prisma Health Richland Hospital — Columbia, South Carolina
  • BI-LO Charities Children's Cancer Center — Greenville, South Carolina
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical data, this bifunctional antibody may exert synergistic activity in patients with EGFR-driv…

Sponsor: Bicara Therapeutics
NCT ID: NCT04429542
Sites in South Carolina:
  • Medical University of South Carolina, Hollings Cancer Center — Charleston, South Carolina
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma

In this Phase I trial for subjects with advanced head \& neck cancer, breast cancer, soft tissue sarcoma or melanoma all subjects will receive open label X-PACT treatment as a intra-tumoral injection. The primary objective will be to estab…

Sponsor: Immunolight, LLC
NCT ID: NCT04389281
Sites in South Carolina:
  • Prisma Health — Greenville, South Carolina
View on ClinicalTrials.gov →
Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in South Carolina:
  • AnMed Health Cancer Center — Anderson, South Carolina
  • Prisma Health Richland Hospital — Columbia, South Carolina
  • McLeod Regional Medical Center — Florence, South Carolina
  • Gibbs Cancer Center-Gaffney — Gaffney, South Carolina
  • Tidelands Georgetown Memorial Hospital — Georgetown, South Carolina
View on ClinicalTrials.gov →
NA Recruiting Network

Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials

The purpose of this study is to evaluate feasibility and acceptability of completing PROs among AYAs randomized to Choice PRO vs Fixed PRO.

Sponsor: Eastern Cooperative Oncology Group
NCT ID: NCT05108298
Sites in South Carolina:
  • AnMed Health Cancer Center — Anderson, South Carolina
  • Saint Joseph's/Candler - Bluffton Campus — Bluffton, South Carolina
  • Prisma Health Cancer Institute - Spartanburg — Boiling Springs, South Carolina
  • Prisma Health Cancer Institute - Easley — Easley, South Carolina
  • Gibbs Cancer Center-Gaffney — Gaffney, South Carolina
View on ClinicalTrials.gov →
Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in South Carolina:
  • Massive Bio SYNERGY-AI site — Greenville, South Carolina
View on ClinicalTrials.gov →
Recruiting Industry

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types. The cancers included in this study are brain, breast, …

Sponsor: Adela, Inc
NCT ID: NCT05366881
Sites in South Carolina:
  • Medical University of South Carolina — Charleston, South Carolina
  • McLeod Health — Florence, South Carolina
View on ClinicalTrials.gov →
NA Recruiting Academic/Other

Multi-Site Trial of Navigation vs Treatment as Usual to Improve Initiation of Timely Adjuvant Therapy

The goal of this clinical trial is to compare the effectiveness of a navigation-based multilevel intervention (ENDURE) with treatment as usual (TAU) to improve the initiation of guideline-adherent postoperative radiation therapy among pati…

Sponsor: Medical University of South Carolina
NCT ID: NCT05793151
Sites in South Carolina:
  • Medical University of South Carolina — Charleston, South Carolina
View on ClinicalTrials.gov →
NA Recruiting Academic/Other

The SNAP Tool for Head and Neck Cancer Survivor-Caregiver Dyads

In this randomized behavioral intervention, head and neck cancer (HNC) survivors and their caregivers (N=176 HNC survivor-caregiver dyads) will be randomized to either Survivorship Needs Assessment Planning (SNAP) or Usual Care (UC) groups…

Sponsor: Medical University of South Carolina
NCT ID: NCT05811936
Sites in South Carolina:
  • Medical University of South Carolina — Charleston, South Carolina
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-07-07